Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotte Thim Hansen

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|December 10, 2002
[The National Patient Registry--clinical databases--not an either or but both and]Bent Ottesen, Charlotte Møller, Charlotte Thim Hansen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 22, 2015
Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of the Treatment-Related Impact Measure-Non-severe Hypoglycemic Events (TRIM-HYPO)Meryl Brod, Lise Højbjerre, Donald M Bushnell, et al.
Alzheimer Disease and Associated Disorders|January 26, 2024
Rescreening on RBANS Delayed Memory Index? Forget About It!Marwan N Sabbagh, Wojciech Michalak, Charlotte Thim Hansen, et al.
Drugs in R&D|April 22, 2016
A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes MellitusChangyu Pan, Jorge L Gross, Wenying Yang, et al.
Diabetes Care|October 30, 2019
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of DiabetesSimon R Heller, John B Buse, Robert Ratner, et al.
JAMA|July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical TrialWendy Lane, Timothy S Bailey, Gregg Gerety, et al.
Neurology|February 20, 2025
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)Philip Scheltens, Alireza Atri, Howard Feldman, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 22, 2020
FLAME: A computerized neuropsychological composite for trials in early dementiaHelen Brooker, Gareth Williams, Adam Hampshire, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 1, 2022
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registersCaroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practiceClifford R Jack, Ana Graf, Samantha C Burnham, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|December 10, 2002
[The National Patient Registry--clinical databases--not an either or but both and]Bent Ottesen, Charlotte Møller, Charlotte Thim Hansen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 22, 2015
Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of the Treatment-Related Impact Measure-Non-severe Hypoglycemic Events (TRIM-HYPO)Meryl Brod, Lise Højbjerre, Donald M Bushnell, et al.
Alzheimer Disease and Associated Disorders|January 26, 2024
Rescreening on RBANS Delayed Memory Index? Forget About It!Marwan N Sabbagh, Wojciech Michalak, Charlotte Thim Hansen, et al.
Drugs in R&D|April 22, 2016
A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes MellitusChangyu Pan, Jorge L Gross, Wenying Yang, et al.
Diabetes Care|October 30, 2019
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of DiabetesSimon R Heller, John B Buse, Robert Ratner, et al.
JAMA|July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical TrialWendy Lane, Timothy S Bailey, Gregg Gerety, et al.
Neurology|February 20, 2025
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)Philip Scheltens, Alireza Atri, Howard Feldman, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 22, 2020
FLAME: A computerized neuropsychological composite for trials in early dementiaHelen Brooker, Gareth Williams, Adam Hampshire, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 1, 2022
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registersCaroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practiceClifford R Jack, Ana Graf, Samantha C Burnham, et al.
Pageof 2